When combining ACPA, RF, and other autoantibodies, we detect autoantibodies in 59.8% of the anti-CCP2-negative RA population, with ACPA fine-specificities found in 34.5%, RF isotypes in 30.1%, and other autoantibodies in 30.3%. This evidence concerns the gene PRTN3 and rheumatoid arthritis.